Compare IFBD & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IFBD | ENVB |
|---|---|---|
| Founded | 2001 | 1994 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.1M |
| IPO Year | 2020 | 2000 |
| Metric | IFBD | ENVB |
|---|---|---|
| Price | $0.89 | $2.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.3K | ★ 235.5K |
| Earning Date | 05-01-2023 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.66 | $0.56 |
| 52 Week High | $1.40 | $13.25 |
| Indicator | IFBD | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 41.84 |
| Support Level | $0.66 | $1.83 |
| Resistance Level | $1.09 | $4.29 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 32.61 | 38.05 |
Infobird Co Ltd is a software-as-a-service (SaaS) provider of AI-powered customer engagement solutions in China. The Company provides standard and customized customer relationship management cloud-based services, including SaaS and business process outsourcing (BPO) services. It generates revenue from the development and sale of software licenses for customized software, as well as from business integration solution services and digital advertising and marketing campaign services. Digital advertising revenue is generated from developing and executing advertising plans based on customer needs, and the Company generally provides limited warranties for work performed under its business integration solution contracts. The Company generates maximum revenue from its operations in Mainland China.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.